CRSP
CRISPR Therapeutics AG
60.31
2 x 44.50
1 x 72.32
bid
ask
+
4.69
8.43%
10:18 AM
timesize
| Ytd | 15.01% | |
| 1y | 16.72% |
56.18
day range
61.68
44.12
52 week range
78.48
| Open | 56.20 | Prev Close | 55.62 | Low | 56.18 | High | 61.68 | Mkt Cap | 5.96B |
| Vol | 735.69K | Avg Vol | 1.72M | EPS | -6.17 | P/E | N/A | Forward P/E | -14.24 |
| Beta | 1.70 | Short Ratio | 15.40 | Inst. Own | 80.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 52.64 | 200-d Avg | 55.56 | 1yr Est | 83.52 |
| Income Statement | |||
| Total Revenue | 1.46M | ||
| Revenues (USD) | 1.46M | ||
| Gross Profit | 1.46M | ||
| Operating Expenses | 131.71M | ||
| Research and Development Expense | 114.52M | ||
| Selling, General and Administrative Expense | 17.18M | ||
| Operating Income | -130.25M | ||
| Income Tax Expense | 839.00K | ||
| Net Income | -122.93M | ||
| Net Income Common Stock | -122.93M | ||
| Net Income Common Stock (USD) | -122.93M | ||
| Consolidated Income | -122.93M | ||
| Earnings per Basic Share | -1.28 | ||
| Earnings per Basic Share (USD) | -1.28 | ||
| Earnings per Diluted Share | -1.28 | ||
| Earning Before Interest & Taxes (EBIT) | -122.09M | ||
| Earning Before Interest & Taxes (USD) | -122.09M | ||
| Weighted Average Shares | 96.05M | ||
| Weighted Average Shares Diluted | 96.05M | ||
| Balance Sheet | |||
| Cash and Equivalents | 430.94M | ||
| Cash and Equivalents (USD) | 430.94M | ||
| Investments | 2.02B | ||
| Investments Current | 2.02B | ||
| Current Assets | 2.45B | ||
| Property, Plant & Equipment Net | 240.85M | ||
| Total Assets | 2.73B | ||
| Debt Current | 18.61M | ||
| Total Debt | 787.64M | ||
| Current Liabilities | 136.29M | ||
| Debt Non-Current | 769.03M | ||
| Total Liabilities | 911.26M | ||
| Accumulated Retained Earnings (Deficit) | -2.07B | ||
| Accumulated Other Comprehensive Income | -1.94M | ||
| Shareholders Equity | 1.81B | ||
| Shareholders Equity (USD) | 1.81B | ||
| Assets Non-Current | 277.46M | ||
| Total Debt (USD) | 787.64M | ||
| Deferred Revenue | 15.34M | ||
| Liabilities Non-Current | 774.98M | ||
| Trade and Non-Trade Payables | 13.65M | ||
| Tax Liabilities | 638.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 4.32M | ||
| Net Cash Flow from Financing | 591.91M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 72.24M | ||
| Capital Expenditure | -504.00K | ||
| Issuance (Purchase) of Equity Shares | 5.44M | ||
| Issuance (Repayment) of Debt Securities | 586.47M | ||
| Net Cash Flow from Investing | -410.74M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -410.24M | ||
| Net Cash Flow from Operations | -108.90M | ||
| Effect of Exchange Rate Changes on Cash | -32.00K | ||
| Share Based Compensation | 16.32M | ||